Nothing Special   »   [go: up one dir, main page]

NO20052281D0 - Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden - Google Patents

Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden

Info

Publication number
NO20052281D0
NO20052281D0 NO20052281A NO20052281A NO20052281D0 NO 20052281 D0 NO20052281 D0 NO 20052281D0 NO 20052281 A NO20052281 A NO 20052281A NO 20052281 A NO20052281 A NO 20052281A NO 20052281 D0 NO20052281 D0 NO 20052281D0
Authority
NO
Norway
Prior art keywords
application
amphiphates
deformability
aggregate
vivo
Prior art date
Application number
NO20052281A
Other languages
English (en)
Other versions
NO20052281L (no
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of NO20052281D0 publication Critical patent/NO20052281D0/no
Publication of NO20052281L publication Critical patent/NO20052281L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20052281A 2002-10-11 2005-05-10 Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden NO20052281L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (2)

Publication Number Publication Date
NO20052281D0 true NO20052281D0 (no) 2005-05-10
NO20052281L NO20052281L (no) 2005-07-07

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052281A NO20052281L (no) 2002-10-11 2005-05-10 Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden

Country Status (22)

Country Link
EP (5) EP1815847A3 (no)
JP (3) JP2006505619A (no)
KR (1) KR20050055723A (no)
CN (1) CN1703199B (no)
AT (1) ATE381316T1 (no)
AU (1) AU2003273977B2 (no)
BR (1) BR0315148A (no)
CA (1) CA2498938A1 (no)
DE (1) DE60318227T2 (no)
DK (1) DK1551370T3 (no)
EA (1) EA010407B1 (no)
ES (1) ES2298566T3 (no)
HK (1) HK1079113A1 (no)
HR (1) HRPK20050421B3 (no)
IS (1) IS7776A (no)
MX (1) MXPA05003744A (no)
NO (1) NO20052281L (no)
NZ (1) NZ538571A (no)
PL (1) PL377202A1 (no)
PT (1) PT1551370E (no)
SI (1) SI1551370T1 (no)
WO (1) WO2004032900A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
CN101842118B (zh) * 2007-09-13 2012-08-08 巴斯夫欧洲公司 疏水蛋白多肽作为渗透增强剂的用途
PL214538B1 (pl) 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
KR20140021950A (ko) * 2009-06-03 2014-02-21 존 찰스 마요 심부 조직 통증 치료 제형
AU2010283998B2 (en) 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
EP2712314A1 (en) * 2011-03-21 2014-04-02 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
WO2012126966A2 (en) * 2011-03-21 2012-09-27 Gregor Cevc Optimised preparations of highly adaptable aggregates
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
JP6375301B2 (ja) * 2012-10-26 2018-08-15 オックスフォード ナノポール テクノロジーズ リミテッド 液滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
AU2014298426B2 (en) * 2013-07-31 2019-07-18 Sequessome Technology Holdings Limited Vesicles
WO2015048554A1 (en) * 2013-09-26 2015-04-02 National University Of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
CN105658782B (zh) * 2013-10-25 2018-08-07 凸版印刷株式会社 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法
EA038613B1 (ru) 2015-06-30 2021-09-23 Секвессом Текнолоджи Холдингс Лимитед Смешанные составы
US20200030457A1 (en) * 2017-04-03 2020-01-30 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
EP4397371A3 (en) 2020-05-19 2024-10-30 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
DE4447277A1 (de) * 1994-12-30 1996-07-04 Hoechst Ag Stabilisierte, phosphormodifizierte Epoxidharze und ihre Verwendung
RU2207844C2 (ru) * 1998-12-23 2003-07-10 Идеа Аг. УСОВЕРШЕНСТВОВАННЫЙ ПРЕПАРАТ ДЛЯ МЕСТНОГО НЕИНВАЗИВНОГО ПРИМЕНЕНИЯ in vivo
ES2173679T3 (es) * 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.

Also Published As

Publication number Publication date
EA010407B1 (ru) 2008-08-29
SI1551370T1 (sl) 2008-06-30
EP1829527A2 (en) 2007-09-05
EA200500632A1 (ru) 2005-12-29
PL377202A1 (pl) 2006-01-23
HK1079113A1 (en) 2006-03-31
AU2003273977A1 (en) 2004-05-04
HRPK20050421B3 (en) 2007-06-30
JP2005213261A (ja) 2005-08-11
JP2009108070A (ja) 2009-05-21
CN1703199A (zh) 2005-11-30
DE60318227T2 (de) 2008-12-04
EP1551370A1 (en) 2005-07-13
CN1703199B (zh) 2010-04-28
ES2298566T3 (es) 2008-05-16
CA2498938A1 (en) 2004-04-22
KR20050055723A (ko) 2005-06-13
EP1815847A2 (en) 2007-08-08
EP1829528A3 (en) 2008-11-05
NO20052281L (no) 2005-07-07
WO2004032900A8 (en) 2005-03-31
JP4555111B2 (ja) 2010-09-29
BR0315148A (pt) 2005-08-16
IS7776A (is) 2005-03-30
PT1551370E (pt) 2008-02-07
DE60318227D1 (de) 2008-01-31
EP1829527A3 (en) 2008-11-05
EP1551370B1 (en) 2007-12-19
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
EP1815846A3 (en) 2008-10-22
NZ538571A (en) 2007-05-31
EP1815847A3 (en) 2008-11-05
JP2006505619A (ja) 2006-02-16
WO2004032900A1 (en) 2004-04-22
ATE381316T1 (de) 2008-01-15
EP1815846A2 (en) 2007-08-08
AU2003273977B2 (en) 2007-07-12
HRP20050421A2 (en) 2005-12-31
MXPA05003744A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
NO20052281D0 (no) Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
WO2004019921A3 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
ES2106735T3 (es) Tratamiento de desordenes mediante la aplicacion de factores de crecimiento de tipo de insulina y analogos.
DE3786005D1 (de) Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff.
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
EE200100388A (et) Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
SI1176976T2 (sl) Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
ATE355290T1 (de) (5-(PYRIDIN-3-YL)-1-AZABICYCLO(3.2.1) OCTAN DERIVATE, DEREN HERSTELLUNG UND DEREN VERWENDUNG IN THERAPEUTIKAß
ITRM990483A0 (it) Composizione per la prevenzione e cura delle disfunzioni e patologie renali di tipo tossico e funzionale.
ITTO930661A0 (it) Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
Labi et al. The Grief Brigade.
Derynck et al. Cell differentiation
WO2001017582A3 (en) Bifurcated shunt drug delivery system and methods of use
HK1027762A1 (en) Use of hydrophilic solvent extract of mushroom in the preparation of drug or food for preventing andtreating kidney disease.
IS7259A (is) 3-Heteróarýl-3,5-díhýdró-4-oxó-4H-pýridasínó[4,5-b]indól-1-karboxamíð afleiður, framleiðsla þeirra og notkun þeirra við meðhöndlun
IT1318516B1 (it) Derivati 2-amminotetralinici otticamente attivi, procedimenti per laloro preparazione e impiego terapeutico delle corrispondenti
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
Wheeler RG-1068 RepliGen
Boulton Combination drug treatment benefits patients with HIV.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application